Notable Price Action: Time to Buy Ocera Therapeutics Inc After Today’s Huge Decline?

Notable Price Action: Time to Buy Ocera Therapeutics Inc After Today's Huge Decline?

The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) is a huge mover today! About 61,679 shares traded hands. Ocera Therapeutics Inc (NASDAQ:OCRX) has declined 22.30% since April 18, 2016 and is downtrending. It has underperformed by 26.73% the S&P500.
The move comes after 5 months negative chart setup for the $46.17M company. It was reported on Nov, 18 by Barchart.com. We have $1.91 PT which if reached, will make NASDAQ:OCRX worth $4.62 million less.

Ocera Therapeutics Inc (NASDAQ:OCRX) Ratings Coverage

Out of 2 analysts covering Ocera Therapeutics (NASDAQ:OCRX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocera Therapeutics has been the topic of 3 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, November 4 by Aegis Capital. The stock has “Buy” rating given by Brean Capital on Tuesday, February 23.

According to Zacks Investment Research, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 1.22 in 2016 Q2. Its up 0.60, from 0.62 in 2016Q1. The ratio increased, as 3 funds sold all Ocera Therapeutics Inc shares owned while 10 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 6.77 million shares or 0.29% less from 6.79 million shares in 2016Q1.
Millennium Management Ltd Liability Com accumulated 516,343 shares or 0% of the stock. Glenmede Tru Na accumulated 11,352 shares or 0% of the stock. Bancshares Of America De has 137 shares for 0% of their US portfolio. Royal Bancorp Of Canada reported 3,293 shares or 0% of all its holdings. Qvt Fincl Lp has 932,086 shares for 0.1% of their US portfolio. Weiss Multi accumulated 0.02% or 112,995 shares. Walleye Trading Ltd Liability Company, a Minnesota-based fund reported 100 shares. Geode Ltd Liability last reported 0% of its portfolio in the stock. Vhcp Ltd Liability has 796,550 shares for 1.57% of their US portfolio. Pura Vida Ltd Limited Liability Company owns 131,000 shares or 0.11% of their US portfolio. Stifel Corporation last reported 32,548 shares in the company. Vanguard Incorporated has invested 0% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX). Bancorp Of Mellon, a New York-based fund reported 34,136 shares. Morgan Stanley has 1,317 shares for 0% of their US portfolio. Manufacturers Life Insur Co The reported 1,755 shares or 0% of all its holdings.

Insider Transactions: Since October 13, 2016, the stock had 1 buying transaction, and 0 insider sales for $6,598 net activity. Bukofzer Stan had bought 2,500 shares worth $6,598 on Thursday, October 13.

Another recent and important Ocera Therapeutics Inc (NASDAQ:OCRX) news was published by Seekingalpha.com which published an article titled: “Ocera Therapeutics: A Speculative Investment” on April 19, 2016.

OCRX Company Profile

Ocera Therapeutics, Inc., incorporated on January 12, 1998, is a clinical-stage biopharmaceutical company. The Firm is focused on acute and chronic orphan liver diseases. The Firm is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. The Firm relies on third-party manufacturers to produce bulk drug substance and drug products required for commercial use and for its clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment